Lindert K, Leav B, Heijnen E, Barrett J, Nicolay U. MF59-Adjuvanted Seasonal Trivalent Influenza Vaccine: Pooled Analysis of Safety in Older Adults ≥65 Years of Age. Int J Infect Dis. 2019 Mar 20.
OBJECTIVE:
To assess the long-term safety of MF59-adjuvanted trivalent influenza vaccine (aIIV3; Fluad?) in adults ≥65 years of age.
METHODS:
Data from 36 primary vaccination and 7 re-vaccination Phase I through III trials were analyzed; 7,532 subjects received aIIV3 and 5,198 subjects a nonadjuvanted trivalent inactivated influenza vaccine (IIV3). These trials were evaluated in 2 data poolings: first-dose randomized controlled trials (FD-RCT) and revaccination trials. Spontaneously reported adverse events (AEs) from post-marketing surveillance were also analyzed.
RESULTS:
The percentages of subjects reporting AEs following vaccination were similar between aIIV3 and IIV3: 24.8% for aIIV3 vs 26.7% for IIV3 (relative risk [RR] 0.94; 95% confidence interval [CI] 0.87-1.01). The percentage of subjects with serious AEs was 6.7% for aIIV3 vs 7.0% for IIV3 (RR 0.95; 95% CI 0.82-1.09). Percentages of subjects with AEs leading to withdrawal, hospitalizations, adverse events of special interest (AESIs), and deaths between vaccination groups were similar. There was no signal of disproportionality for AESIs associated with aIIV3 compared to IIV3 in the post-marketing database.
CONCLUSIONS:
This integrated safety analysis demonstrates an acceptable safety profile for aIIV3 in adults ≥65 years of age.
To assess the long-term safety of MF59-adjuvanted trivalent influenza vaccine (aIIV3; Fluad?) in adults ≥65 years of age.
METHODS:
Data from 36 primary vaccination and 7 re-vaccination Phase I through III trials were analyzed; 7,532 subjects received aIIV3 and 5,198 subjects a nonadjuvanted trivalent inactivated influenza vaccine (IIV3). These trials were evaluated in 2 data poolings: first-dose randomized controlled trials (FD-RCT) and revaccination trials. Spontaneously reported adverse events (AEs) from post-marketing surveillance were also analyzed.
RESULTS:
The percentages of subjects reporting AEs following vaccination were similar between aIIV3 and IIV3: 24.8% for aIIV3 vs 26.7% for IIV3 (relative risk [RR] 0.94; 95% confidence interval [CI] 0.87-1.01). The percentage of subjects with serious AEs was 6.7% for aIIV3 vs 7.0% for IIV3 (RR 0.95; 95% CI 0.82-1.09). Percentages of subjects with AEs leading to withdrawal, hospitalizations, adverse events of special interest (AESIs), and deaths between vaccination groups were similar. There was no signal of disproportionality for AESIs associated with aIIV3 compared to IIV3 in the post-marketing database.
CONCLUSIONS:
This integrated safety analysis demonstrates an acceptable safety profile for aIIV3 in adults ≥65 years of age.
See Also:
Latest articles in those days:
- Characterisation of a human monoclonal antibody targeting a conserved epitope at the base of the HA head of influenza A(H3N2) virus 6 hours ago
- An outbreak report of Influenza A(H3) among residents of a large nursing home in northern Italy: attack rates, clinical features and outcomes 19 hours ago
- Susceptibility of calves fed unpasteurized milk from cows infected with highly pathogenic avian influenza H5N1 19 hours ago
- Functional mapping of IFITM3 resolves its antiviral core and deciphers human influenza susceptibility 19 hours ago
- Comparison of the adjuvant effect of AS01, AS03 and alum on the immune response to GMP-grade H5N1 antigen in guinea pigs 2 days ago
[Go Top] [Close Window]
